GSA Capital Partners’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRV
GSA Capital Partners's ACRV Position: Q3 2026 in Review
GSA Capital Partners increased its Acrivon Therapeutics (ACRV) stake by 4.5% in Q3 2026, buying an estimated $17K and bringing the position to 209,355 shares worth $429K. The position accounts for 0.03% of the portfolio, ranked #1164.
GSA Capital Partners first reported a position in ACRV in Q1 2026 and has held it in 3 quarters since. 46 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.
- GSA Capital Partners held 209,355 shares of Acrivon Therapeutics worth $429K as of Q3 2026.
- GSA Capital Partners bought 8,940 Acrivon Therapeutics shares in Q3 2026, an estimated $17K.
- Acrivon Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q3 2026, its #1164 holding.
- GSA Capital Partners first reported a position in Acrivon Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.